Dialysis News and Research RSS Feed - Dialysis News and Research

When your kidneys are healthy, they clean your blood. They also make hormones that keep your bones strong and your blood healthy. When your kidneys fail, you need treatment to replace the work your kidneys used to do. Unless you have a kidney transplant, you will need a treatment called dialysis.

There are two main types of dialysis: hemodialysis and peritoneal dialysis. Both types filter your blood to rid your body of harmful wastes, extra salt and water. Hemodialysis does that with a machine. Peritoneal dialysis uses the lining of your abdomen, called the peritoneal membrane, to filter your blood. Each type has both risks and benefits. They also require that you follow a special diet. Your doctor can help you decide the best type of dialysis for you.
DaVita Kidney Care expands care of kidney patients in Malaysia

DaVita Kidney Care expands care of kidney patients in Malaysia

DaVita Kidney Care, a division of DaVita HealthCare Partners Inc. and a leading provider of kidney care services, today announced it acquired three hemodialysis centers from Malaysian dialysis provider Sinar Indentiti Sbn Bhd, further expanding its care of kidney patients in the country. [More]

Diaverum acquires its seventh kidney centre in Chile

Diaverum, one of the world's leading renal care service providers, has acquired its seventh kidney centre Chile. The Diaseal clinic, located in Puente Alto, a highly populated and fast growing district in the south of capital Santiago, features 18 stations which are used to treat 100 patients with haemodialysis (HD). [More]

Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD) in patients who are not dependent on dialysis. [More]
NEPHRON+ project improves lives of kidney failure patients by developing wearable artificial kidney device

NEPHRON+ project improves lives of kidney failure patients by developing wearable artificial kidney device

End stage kidney disease is a global public health problem with an estimated 2.4 million patients on dialysis. The number of new cases is rising (7-8% annually) due to population ageing and increased diabetes prevalence. [More]
Students competing in Center for Medical Innovation’s Annual Bench-to-Bedside Competition win nearly $72,000

Students competing in Center for Medical Innovation’s Annual Bench-to-Bedside Competition win nearly $72,000

University of Utah students competing in the Center for Medical Innovation's Annual Bench-to-Bedside Competition were awarded nearly $72,000 in prize money on April 9 at the Utah State Capitol. [More]
Lin28 gene may hold clues to regeneration of damaged kidneys in adults

Lin28 gene may hold clues to regeneration of damaged kidneys in adults

​Nearly one-third of cases of Wilms tumor, a pediatric cancer of the kidney, are linked to a gene called Lin28, according to research from Boston Children's Hospital. Mice engineered to express Lin28 in their kidneys developed Wilms tumor, which regressed when Lin28 was withdrawn, indicating that strategies aimed at blocking or deactivating the gene hold therapeutic promise for children with Wilms. [More]
President of ASN urges Congress to spur scientific innovation in kidney research through federal prize competition

President of ASN urges Congress to spur scientific innovation in kidney research through federal prize competition

Today the President of the American Society of Nephrology (ASN) urged Congress to spur scientific innovation in kidney research through a federal prize competition. [More]

Kidney disease patients with poor quality of life at increased risk of developing heart problems

Kidney disease patients with poor quality of life are at increased risk of experiencing progression of their disease and of developing heart problems, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. The findings suggest that quality of life measurements may have important prognostic value in these individuals. [More]

Patients who stay longer in ICU have substantial physical impairments 2 years later

Patients have substantial physical impairments even two years after being discharged from the hospital after a stay in an intensive care unit (ICU), new Johns Hopkins research suggests. [More]
UCLA scientist wins $3M gift for research on structural properties of key proteins in kidney

UCLA scientist wins $3M gift for research on structural properties of key proteins in kidney

UCLA Scientist Dr. Ira Kurtz has received a $3 million gift from the Donald T. Sterling Foundation to fund research on the structural properties of key proteins in the kidney that affect its function in health and disease. [More]
NxStage Medical receives American Red Cross Northeast Chapter's Workplace Hero Award

NxStage Medical receives American Red Cross Northeast Chapter's Workplace Hero Award

NxStage Medical Inc., a leading manufacturer of home dialysis products, today announced the Company has been awarded the 2014 Workplace Hero Award by the Northeast Chapter of the American Red Cross. [More]
Research roundup: Distance from a transplant center; Medicaid prenatal care; metastasis of email; profiting from Medicare Advantage

Research roundup: Distance from a transplant center; Medicaid prenatal care; metastasis of email; profiting from Medicare Advantage

Centralization of specialized health care services such as organ transplantation and bariatric surgery is advocated to improve quality, increase efficiency, and reduce cost. [More]

Nephros’ total revenues decrease $67,000 to 4% in the year ended December 31, 2012

Nephros, Inc., a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, announced today financial results for the three months and full year ended December 31, 2013. [More]

Baxter plans to create two independent global healthcare companies

Baxter International Inc. today announced plans to create two separate, independent global healthcare companies -- one focused on developing and marketing innovative biopharmaceuticals and the other on life-saving medical products. Both will be global leaders in their respective markets. [More]

FMCNA introduces newly branded Frenova Renal Research business

Fresenius Medical Care North America, the world's largest provider of dialysis services, today introduced its newly branded Frenova Renal Research business, the only Phase I-IV drug and device clinical development partner dedicated exclusively to renal research. [More]

AM-Pharma reports positive results from recAP Phase I trial for Acute Kidney Injury

AM-Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces the results of its Phase I trial with both single and multiple ascending doses, which demonstrate that recAP is safe and well tolerated at all doses. [More]
Renal Ventures Management publishes first cookbook of kidney friendly recipes for renal patients

Renal Ventures Management publishes first cookbook of kidney friendly recipes for renal patients

In recognition of Kidney Health Awareness Month, Renal Ventures Management, LLC (RVM), a leading provider of dialysis services for patients suffering from chronic kidney failure, has published its first cookbook of kidney friendly recipes for it renal patients and their families. [More]

Otsuka obtains regulatory approval in Japan for pharmacological treatment of ADPKD

Otsuka Pharmaceutical Co., Ltd. today announced it has become the first company in the world to obtain regulatory approval for a pharmacological treatment of autosomal dominant polycystic kidney disease (ADPKD). Samsca (generic name: tolvaptan) has been approved in Japan in 7.5-mg and 15-mg tablet forms for extended use for the additional indication of ADPKD. Also, the new dosage form of 30-mg Samsca tablets has received approval for the indication of ADPKD. [More]

Sparton completes all-cash transaction to acquire Aubrey Group

Sparton Corporation announces that it completed an all-cash transaction to acquire Aubrey Group, Inc., an $8 million revenue business, on March 17, 2014. Aubrey will continue to service its current and future customers out of its Irvine, CA location. [More]

Scientists discover that natural product in grapefruit can prevent kidney cysts

Scientists at Royal Holloway, University of London, have discovered that a natural product found in grapefruit can prevent kidney cysts from forming. [More]